Will MetLife Egypt and AXA Egypt and Bupa Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Anktiva is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Anktiva at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative quote provided at intake. Delivered quote within 24h.Get my quote

Anktiva access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Anktiva (nogapendekin alfa inbakicept-pmln) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Anktiva (nogapendekin alfa inbakicept-pmln) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours, in adults, given with BCG through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Anktiva reaches patients in Egypt

Anktiva (nogapendekin alfa inbakicept-pmln, an interleukin-15 superagonist N-803 complex from ImmunityBio) received US FDA approval in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours, in adults, given intravesically in combination with Bacillus Calmette-Guerin per the FDA label at accessdata.fda.gov/scripts/cder/daf. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg shows no public registration record for nogapendekin alfa inbakicept-pmln or Anktiva as of 2026-06-01. Egyptian patients access the drug through the Personal Importation of Unregistered Medicines pathway operated by the EDA Central Administration for Pharmaceutical Affairs under Pharmacy Practice Law No. 127 of 1955 read with Health Minister Decree No. 296 of 2009 and the post-2019 EDA framework at edaegypt.gov.eg. For an Anktiva application the treating Egyptian-licensed urologist or uro-oncologist issues a stamped medical report documenting biopsy-confirmed non-muscle-invasive bladder cancer with CIS, prior BCG induction with documented unresponsiveness per the FDA-aligned definition (persistent or recurrent CIS within 12 months of adequate BCG), patient unfitness or refusal of radical cystectomy, and the planned intravesical Anktiva-plus-BCG induction-and-maintenance schedule referencing the QUILT-3.032 single-arm pivotal study at clinicaltrials.gov/NCT03022825. EDA does not publish a fixed processing-time SLA; patient-organisation and consultancy reporting indicates one to three weeks turnaround when documentation is complete, longer for cold-chain biologic verification. Each shipment requires a fresh permit with conventional up to three-month supply per application; the maintenance schedule drives re-filing cadence. The hospital-led institutional-import lane is the common path for Anktiva because the intravesical procedure is hospital-based and BCG co-administration sequencing requires institutional coordination.

Where Anktiva is dispensed in Egypt

Anktiva is administered as an intravesical instillation in the urology outpatient procedure suite or day-case unit, with sequenced BCG co-administration and cystoscopic surveillance for response assessment. The Egyptian tertiary centres equipped for urology oncology intravesical therapy and named-patient specialty-drug import include the National Cancer Institute at Cairo University, the country's flagship public cancer centre with a Urology Oncology service at nci.cu.edu.eg; Cairo University Hospitals (Kasr Al-Ainy) Department of Urology at kasralainy.edu.eg; Ain Shams University Hospitals Department of Urology in Cairo; Mansoura Urology and Nephrology Centre, a regionally recognised reference centre for urological oncology at mans.edu.eg; and Alexandria University Hospitals Department of Urology. Among the charitable and private tertiary tier, Baheya Foundation at baheya.org is breast-oncology specialised and not the appropriate Anktiva site; Cleopatra Hospitals Group at cleopatrahospital.com and As-Salam International Hospital in Cairo carry urology service lines and have handled named-patient specialty imports for adult oncology. Mansoura Urology and Nephrology Centre and the NCI are the most frequent dispensing nodes for intravesical specialty therapy given their volume and BCG-program integration.

What Anktiva costs in Egypt

The US wholesale acquisition cost for Anktiva is reported by ImmunityBio at approximately USD 95,000 per 400 mcg single-dose vial used in the FDA-labelled induction schedule (six weekly instillations of 400 mcg each across induction and a maintenance schedule across two years for responders), with full-course annual drug-only spend reaching USD 287,000 to USD 337,000 per cycle depending on the maintenance arm length per manufacturer pricing disclosures referenced on the FDA channel at accessdata.fda.gov/scripts/cder/daf. Price snapshot: 2026-06-01. No public local-currency price for Anktiva in Egyptian Pounds is observed in the EDA pricing committee output or the Unified Procurement Authority disclosures at upa.gov.eg as of 2026-06-01; do not estimate. The Central Bank of Egypt USD reference rate has been volatile through 2024 to 2026; families wiring in USD avoid intra-process FX exposure. Cost layers beyond the drug include cold-chain international logistics (Anktiva requires refrigerated 2 to 8 degrees Celsius handling with continuous monitoring), the EDA permit and customs duties, the dispensing facility intravesical-procedure fees, and the Reserve Meds concierge fee itemised separately on every firm quote.

Funding and access barriers for Anktiva in Egypt

Specialty oncology funding for adult urology in Egypt sits primarily with public-sector facilities and case-by-case mechanisms rather than a single standing programme. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg, established under Law No. 2 of 2018, is the statutory payer for insured citizens in implementation governorates and co-runs the joint HTA process with the Unified Procurement Authority; Anktiva is not on the UHIA reimbursement list as of 2026-06-01. The Treatment at State Expense scheme (Nafaqat Ala Al-Dawla) administered through MOHP funds case-by-case high-cost adult oncology treatment for Egyptian nationals lacking means, with committee review on clinical and means grounds, and bladder-cancer cases have used this route historically for BCG and chemotherapeutic agents. The Saudi-Egyptian collaborative oncology funding initiatives administered through KSrelief have supported limited high-cost imports for defined humanitarian cases. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) typically exclude or sub-limit unregistered named-patient imports on standard retail policies; corporate group plans may include with prior authorisation and documented BCG-unresponsiveness. Out-of-pocket spending dominates per World Bank data at data.worldbank.org; for adult oncology named-patient imports the dominant pattern is self-pay with limited supplementation by Treatment at State Expense and family fundraising. BCG continuity is a parallel access constraint families and dispensing centres plan around because Anktiva is FDA-labelled only in combination with BCG.

Recent regulatory and access news for Anktiva

The FDA accelerated approval of Anktiva in April 2024 was based on the QUILT-3.032 single-arm complete-response and duration-of-response data; the European Medicines Agency has not authorised the drug in the EU as of 2026-06-01 per the EMA medicines portal at ema.europa.eu/en/medicines, which constrains the reference-authority options Egyptian physicians can cite to the FDA listing. ImmunityBio reported expanded commercial supply through the second half of 2025 and has continued patient-access program discussions in MENA per public investor disclosures; no public Egypt-specific ImmunityBio access programme has been announced as of 2026-06-01. UHIA and the Unified Procurement Authority have continued phased UHI rollout per UHIA bulletins at uhia.gov.eg, and the payer mix for adult oncology specialty drugs differs by governorate. No drug-specific EDA bulletin for Anktiva or nogapendekin alfa over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Anktiva cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Anktiva specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Anktiva case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Anktiva is delivered intravesically in combination with BCG on a defined induction-and-maintenance schedule; cystoscopic surveillance and BCG availability govern treatment continuity.

Next step

If your Egyptian physician has prescribed Anktiva and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Anktiva case Or message us on WhatsApp